Should aspirin be replaced with ADP blockers and anti-GPVI to manage thrombosis?

Platelets have a pivotal role in maintaining cardiovascular homeostasis. They are kept docile by endothelial-derived mediators. Aberration haemostatic balance predisposes an individual to elevated risk of prothrombotic environment. Anti-platelet therapy has been key component reduce this risk. However, understanding how these medications affect the between activation and inhibition platelets is critical. There no evidence that anti-platelet – aspirin, may not be most efficacious medicine choice, as it can compromise both platelet pathways. In review, rationale aspirin anti-thrombotic drug critically discussed. This review looks at recently published trials raising questions about efficacy safety countering diseases. increasing portfolio identifies although very cheap accessible drug, used manner always beneficial patient, more nuanced targeted use increase its clinical benefit maximize patient response. The raise potential for changes dual therapy. highlights need ensure treatment effective other therapies well CVD patients their standard personalized approaches.